Compare NOAH & STRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NOAH | STRO |
|---|---|---|
| Founded | 2005 | 2003 |
| Country | China | United States |
| Employees | N/A | 133 |
| Industry | Investment Managers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 653.4M | 524.8M |
| IPO Year | 2010 | N/A |
| Metric | NOAH | STRO |
|---|---|---|
| Price | $10.26 | $31.08 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 9 |
| Target Price | $11.00 | ★ $31.33 |
| AVG Volume (30 Days) | 71.2K | ★ 265.8K |
| Earning Date | 05-27-2026 | 05-11-2026 |
| Dividend Yield | ★ 5.66% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $5.71 | N/A |
| P/E Ratio | $13.29 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.53 | $0.67 |
| 52 Week High | $12.84 | $43.85 |
| Indicator | NOAH | STRO |
|---|---|---|
| Relative Strength Index (RSI) | 44.73 | 54.35 |
| Support Level | $9.83 | $23.53 |
| Resistance Level | $10.77 | $43.85 |
| Average True Range (ATR) | 0.27 | 2.84 |
| MACD | -0.00 | 0.54 |
| Stochastic Oscillator | 35.71 | 94.41 |
Noah Holdings Ltd is a wealth management service provider offering comprehensive advisory services on investment and asset allocation, mainly for Mandarin-speaking high-net-worth (HNW) investors. The company's operating segments are Domestic public securities, Domestic asset management, Domestic insurance, Overseas wealth management, Overseas asset management, Overseas insurance and comprehensive services, and Headquarters. Maximum revenue is generated from its Domestic asset management business, which manages private equity funds, real estate equity funds, and private secondary products. The domestic asset management operations focus on managing primary market exits and cross-border ETF products in the secondary market. Geographically, it derives maximum revenue from Mainland China.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. Company's wholly-owned product candidate is STRO-004, a single homogeneous ADC directed against tissue factor which are developing for the treatment of solid tumors. The company also pipeline contains STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.